BioXcel Therapeutics, Inc. (BTAI) Social Stream



BioXcel Therapeutics, Inc. (BTAI): $14.27

1.07 (+8.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About BTAI

$BTAI I am long and adding. Plenty of cash and a strong list of news that can come in the next 6 months. I get the frustration on the stock price but it has been on extremely low volume and a very down XBI. If the news comes as expected then the below analyst price targets could be reached.

A number of other research analysts have also weighed in on BTAI. HC Wainwright reduced their target price on BioXcel Therapeutics from $176.00 to $140.00 and set a “buy” rating for the company in a report on Monday, June 28th. Truist Securities cut their price objective on BioXcel Therapeutics from $128.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, June 23rd. Ten analysts have rated the stock with a buy rating, BioXcel Therapeutics currently has a consensus rating of “Buy” and an average price target of $102.00.

https://www.tickerreport.com/banking-finance/7766981/jefferies-financial-group-comments-on-bioxcel-therapeutics-inc-s-q3-2021-earnings-nasdaqbtai.html
stockguru8888, published August 14, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3853 seconds.